CBER/CDER Consolidation: Weiss Named Acting Director Of New ODE VI
Executive Summary
CBER Office of Therapeutics Research & Review Acting Director Sharon Risso will continue to serve as the point person for biologics staff transition questions after the consolidation with FDA's drugs center
You may also be interested in...
FDA Reorganization Plan Would Eliminate One ODE, Split Neuropharm Division
FDA is planning to split the Division of Neuropharmacological Drug Products into two divisions - neurology and psychiatry - as part of the upcoming reorganization of the Office of New Drugs
FDA Reorganization Plan Would Eliminate One ODE, Split Neuropharm Division
FDA is planning to split the Division of Neuropharmacological Drug Products into two divisions - neurology and psychiatry - as part of the upcoming reorganization of the Office of New Drugs
FDA names ODE VI deputy director
David Ross, MD/PhD, has been appointed deputy director of Center for Drug Evaluation & Research's Office of Drug Evaluation VI. Effective April 18, he will report to office director Karen Weiss, MD. Weiss was named to the post in June (1"The Pink Sheet" June 23, 2003, p. 24)...